Cargando…

Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug

AIM: This work shows the development of pulsatile capsular pellets of metformin hydrochloride and its characterisation. MATERIAL AND METHODS: The novel drug delivery system consisted of hydroxy propyl cellulose Type H. It has a lag time modifier and Eudragit L-100 and Eudragit S-100 in different con...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Rahul, Selvamurthy, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574743/
https://www.ncbi.nlm.nih.gov/pubmed/33100797
http://dx.doi.org/10.4103/jpbs.JPBS_203_19
_version_ 1783597686350413824
author Pandey, Rahul
Selvamurthy, William
author_facet Pandey, Rahul
Selvamurthy, William
author_sort Pandey, Rahul
collection PubMed
description AIM: This work shows the development of pulsatile capsular pellets of metformin hydrochloride and its characterisation. MATERIAL AND METHODS: The novel drug delivery system consisted of hydroxy propyl cellulose Type H. It has a lag time modifier and Eudragit L-100 and Eudragit S-100 in different concentrations as pH-dependent release modifier in the gastrointestinal tract. The pellets were subjected to in vitro release studies using USP dissolution apparatus type-II in distilled water, phosphate buffer of pH 6.8, and 0.1 N HCl and methanol. Ultraviolet (UV), infrared (IR), high-performance liquid chromatography (HPLC), and mass spectroscopy were performed for active pharmaceutical ingredients and formulations. RESULT: The study was characterized by the complete release of the drug in pulses after a well-defined lag time of 6 h (±0.20) (period of no drug release) for the treatment of type II diabetes mellitus. CONCLUSION: The stability studies on the selected formulation of Metformin were found to be stable, with shelf life of 1.94 years. Hence it may be concluded that the newly formulated pulsatile drug delivery systems of Metformin Hydrochloride, when ingested at the bed time in the night, produce effective control of the increased blood glucose level after intake of meals by allowing the drug to release after a lag time of 6 h (after meals).
format Online
Article
Text
id pubmed-7574743
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-75747432020-10-22 Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug Pandey, Rahul Selvamurthy, William J Pharm Bioallied Sci Original Article AIM: This work shows the development of pulsatile capsular pellets of metformin hydrochloride and its characterisation. MATERIAL AND METHODS: The novel drug delivery system consisted of hydroxy propyl cellulose Type H. It has a lag time modifier and Eudragit L-100 and Eudragit S-100 in different concentrations as pH-dependent release modifier in the gastrointestinal tract. The pellets were subjected to in vitro release studies using USP dissolution apparatus type-II in distilled water, phosphate buffer of pH 6.8, and 0.1 N HCl and methanol. Ultraviolet (UV), infrared (IR), high-performance liquid chromatography (HPLC), and mass spectroscopy were performed for active pharmaceutical ingredients and formulations. RESULT: The study was characterized by the complete release of the drug in pulses after a well-defined lag time of 6 h (±0.20) (period of no drug release) for the treatment of type II diabetes mellitus. CONCLUSION: The stability studies on the selected formulation of Metformin were found to be stable, with shelf life of 1.94 years. Hence it may be concluded that the newly formulated pulsatile drug delivery systems of Metformin Hydrochloride, when ingested at the bed time in the night, produce effective control of the increased blood glucose level after intake of meals by allowing the drug to release after a lag time of 6 h (after meals). Wolters Kluwer - Medknow 2020 2020-07-18 /pmc/articles/PMC7574743/ /pubmed/33100797 http://dx.doi.org/10.4103/jpbs.JPBS_203_19 Text en © 2020 Journal of Pharmacy and Bioallied Sciences http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Pandey, Rahul
Selvamurthy, William
Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
title Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
title_full Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
title_fullStr Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
title_full_unstemmed Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
title_short Design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
title_sort design and in vitro characterization of novel pulsatile delivery system of biguanide antidiabetic drug
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7574743/
https://www.ncbi.nlm.nih.gov/pubmed/33100797
http://dx.doi.org/10.4103/jpbs.JPBS_203_19
work_keys_str_mv AT pandeyrahul designandinvitrocharacterizationofnovelpulsatiledeliverysystemofbiguanideantidiabeticdrug
AT selvamurthywilliam designandinvitrocharacterizationofnovelpulsatiledeliverysystemofbiguanideantidiabeticdrug